Please assess the completion status of the following clinical trial:

Trial Title: Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male volunteers aged between 18 and 45 years for the adult group, and children of both sexes aged 5-9 years for schoolchildren group~2. Written informed consent obtained from the volunteer (adult) or guardian/ legal representative (children). In case patient is illiterate, an impartial witness should be present during the entire consent procedure~3. Free of obvious health problems as established by medical history and clinical examination before entering the study~4. Body Mass Index between 18 and 30 for adults; MUAC less than 12 for children~Exclusion Criteria:~1. Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period and safety follow-up~2. Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose~3. Any chronic drug therapy to be continued during the study period~4. Any confirmed or suspected acquired immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection, or history of congenital or hereditary immunodeficiency~5. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine~6. Acute disease at the time of enrollment. Acute disease is defined as the presence of a moderate or severe illness with or without fever (defined as temperature more than 37.5°C)~7. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests~8. Acute or chronic diabetes~9. History of chronic alcohol consumption and/or intravenous drug abuse

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 PEV301&302 (Type: EXPERIMENTAL): The vaccine includes two antigens (CSP and AMA1- derived)in combination and formulated with virosomes
- 2 Influenza vaccine (Type: ACTIVE_COMPARATOR): Inflexal V is the comparator that includes 3 antigens from flu formulated in virosomes

Based on this trial design, predict the completion outcome and termination type (if applicable).